Comerica Bank trimmed its position in Humana Inc (NYSE:HUM) by 19.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,929 shares of the insurance provider’s stock after selling 6,438 shares during the quarter. Comerica Bank’s holdings in Humana were worth $8,774,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Livforsakringsbolaget Skandia Omsesidigt boosted its stake in Humana by 13.7% during the 2nd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,493 shares of the insurance provider’s stock valued at $742,000 after purchasing an additional 300 shares during the last quarter. Xact Kapitalforvaltning AB boosted its stake in Humana by 2.7% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 26,255 shares of the insurance provider’s stock valued at $7,814,000 after purchasing an additional 694 shares during the last quarter. Raymond James Trust N.A. boosted its stake in Humana by 19.8% during the 2nd quarter. Raymond James Trust N.A. now owns 956 shares of the insurance provider’s stock valued at $284,000 after purchasing an additional 158 shares during the last quarter. Daiwa SB Investments Ltd. boosted its stake in Humana by 27.9% during the 2nd quarter. Daiwa SB Investments Ltd. now owns 780 shares of the insurance provider’s stock valued at $232,000 after purchasing an additional 170 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. boosted its stake in Humana by 15.2% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 82,557 shares of the insurance provider’s stock valued at $24,571,000 after purchasing an additional 10,889 shares during the last quarter. Institutional investors own 92.62% of the company’s stock.
In related news, CEO Bruce D. Broussard sold 18,000 shares of the firm’s stock in a transaction on Monday, September 10th. The stock was sold at an average price of $328.66, for a total value of $5,915,880.00. Following the transaction, the chief executive officer now directly owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Elizabeth D. Bierbower sold 3,092 shares of the firm’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $330.00, for a total value of $1,020,360.00. Following the completion of the transaction, the insider now directly owns 14,289 shares in the company, valued at $4,715,370. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by company insiders.
A number of equities analysts have recently issued reports on the company. Credit Suisse Group raised their price target on Humana from $370.00 to $390.00 and gave the stock an “outperform” rating in a research note on Thursday. MED raised their price target on Humana from $350.00 to $373.00 and gave the stock an “outperform” rating in a research note on Thursday. SunTrust Banks restated a “hold” rating and issued a $350.00 price target on shares of Humana in a research note on Thursday, August 2nd. Cowen assumed coverage on Humana in a research note on Monday, September 17th. They issued a “market perform” rating and a $372.00 price target on the stock. Finally, Royal Bank of Canada restated a “hold” rating and issued a $318.00 price target on shares of Humana in a research note on Thursday, August 2nd. Seven analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Humana has a consensus rating of “Buy” and a consensus price target of $352.30.
Shares of Humana stock opened at $338.95 on Friday. Humana Inc has a one year low of $231.90 and a one year high of $355.88. The firm has a market capitalization of $45.71 billion, a P/E ratio of 28.95, a P/E/G ratio of 1.65 and a beta of 1.03. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, November 7th. The insurance provider reported $4.58 EPS for the quarter, topping the Zacks’ consensus estimate of $4.29 by $0.29. Humana had a return on equity of 17.43% and a net margin of 2.48%. The company had revenue of $14.21 billion for the quarter, compared to analysts’ expectations of $13.97 billion. During the same period last year, the firm earned $3.39 EPS. As a group, analysts forecast that Humana Inc will post 14.44 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, January 25th. Investors of record on Monday, December 31st will be issued a $0.50 dividend. The ex-dividend date is Friday, December 28th. This represents a $2.00 dividend on an annualized basis and a yield of 0.59%. Humana’s dividend payout ratio is currently 17.08%.
COPYRIGHT VIOLATION WARNING: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/11/10/humana-inc-hum-holdings-lowered-by-comerica-bank.html.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.